Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6.

scientific article

Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P698PubMed publication ID12858472

P50authorJohn D ReveilleQ67485113
Maria E Suarez-AlmazorQ89359620
P2093author name stringGabriele Valentini
Peter A Merkel
Daniel E Furst
Philip J Clements
OMERACT 6
P433issue7
P407language of work or nameEnglishQ1860
P304page(s)1630-1647
P577publication date2003-07-01
P1433published inThe Journal of RheumatologyQ7743623
P1476titleCurrent status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6
P478volume30

Reverse relations

cites work (P2860)
Q49860214A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography: Outcome Measures for Systemic Sclerosis-Related Raynaud's Phenomenon.
Q52374296A multi-national qualitative research study exploring the patient experience of Raynaud's phenomenon in systemic sclerosis.
Q30359351A preliminary study of skin ultrasound in diffuse cutaneous systemic sclerosis: Does skin echogenicity matter?
Q46755874A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis
Q47835767Assessment of skin involvement in systemic sclerosis
Q60954541Behaviour change interventions for the management of Raynaud's phenomenon: a systematic literature review
Q37730018Biomarkers in systemic sclerosis
Q36175068Clinical Outcome Assessments: Conceptual Foundation-Report of the ISPOR Clinical Outcomes Assessment - Emerging Good Practices for Outcomes Research Task Force
Q37460792Development of a provisional core set of response measures for clinical trials of systemic sclerosis
Q37931049Evaluating factors influencing screening for pulmonary hypertension in systemic sclerosis: does disparity between available guidelines influence clinical practice?
Q37993979Graft-versus-host disease: part II. Management of cutaneous graft-versus-host disease
Q35784089Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise
Q35638054Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study
Q46256178Muscle involvement in systemic sclerosis: points to consider in clinical trials
Q39322803Musculoskeletal Involvement in SSc Is Associated with Worse Scores on Short Form-36 and Scleroderma Health Assessment Questionnaire and Lower Tumor Necrosis Factor-α Gene Expression in Peripheral Blood Mononuclear Cells
Q37586400New directions for patient-centred care in scleroderma: the Scleroderma Patient-centred Intervention Network (SPIN).
Q36821503Outcome measures in systemic sclerosis: an update on instruments and current research
Q33607935Patient-reported outcome assessment in vasculitis may provide important data and a unique perspective
Q35977294Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis
Q45938471Points to consider for designing trials in systemic sclerosis patients with arthritic involvement.
Q45995241Points to consider in renal involvement in systemic sclerosis.
Q48442372Predictors of health-related quality of life and fatigue in systemic sclerosis: evaluation of the EuroQol-5D and FACIT-F assessment tools
Q38180018Quantitating skin fibrosis: innovative strategies and their clinical implications
Q34109827Reliability and validity of the delta finger-to-palm (FTP), a new measure of finger range of motion in systemic sclerosis
Q35851777Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis
Q30372810Skin imaging in systemic sclerosis.
Q35638700Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test
Q36758822The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis
Q40002833The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis
Q34979209The association of body image dissatisfaction and pain with reduced sexual function in women with systemic sclerosis
Q37460765The symptom burden index: development and initial findings from use with patients with systemic sclerosis
Q34727670Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards
Q37460808Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial
Q79804182[Systemic sclerosis - diagnosis and classification]

Search more.